14464-10-9

Usage

Uses

1. Used in Pharmaceutical Industry:
Benzyl 3-hydroxypropionate is used as an intermediate for the synthesis of Cyclophosphamide metabolites, which are essential in the development of drugs for various medical conditions. Its role in the pharmaceutical industry is crucial for the production of life-saving medications.
2. Used in Chemical Synthesis:
As a versatile organic compound, benzyl 3-hydroxypropionate is used as a building block in the synthesis of various other chemicals and compounds. Its unique structure allows it to be a valuable component in the creation of new molecules with potential applications in various fields.
3. Used in Research and Development:
Benzyl 3-hydroxypropionate is also utilized in research and development settings, where it can be studied for its potential applications and properties. This may include exploring its use in drug discovery, material science, or other areas of scientific inquiry.

InChI:InChI=1/C10H12O3/c11-7-6-10(12)13-8-9-4-2-1-3-5-9/h1-5,11H,6-8H2

Upstream product

• 100-39-0 benzyl bromide 
• 503-66-2 3-hydroxypropionic acid 
• 57-57-8 β-Propiolactone 
• 100-51-6 benzyl alcohol 

Downstream Products

• 1026586-00-4 5-(3-Benzyl-phenyl)-3-hydroxy-2-hydroxymethyl-pentanoic acid benzyl ester 
• 1025909-56-1 3-Hydroxy-2-hydroxymethyl-5-[3-(3-phenyl-propyl)-phenyl]-pentanoic acid benzyl ester 

Relevant academic research and scientific papers

AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE

The present invention provides amino ester compounds, salts, and pharmaceutical formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

NOVEL COMPOUNDS

Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

ANGIOTENSIN II RECEPTOR ANTAGONISTS

A compound having the structure wherein R is, for example, Y is selected from the group consisting of 1) R5, 2) -C(R1R2)(C(R3R4))0-1Y1R5, and 3) -C(R1R2)-O-Y1R5; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1-4 alkyl; R5 is; Y1 is selected from the group consisting of C(O)-O- and P(O)(OR6)-O-; and R6 is hydrogen or CH3, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.

Amino-acids and peptides. Part VI. The synthesis, by twinning, of cyclodepsipeptides related to serratamolide

A fourteen-membered cyclodepsipeptide has been synthesised by the interaction of two molecules of β-L-leucyloxy-propionyl chloride. A similar synthesis utilising β-(O-t-butyl-DL-seryloxy)propionyl chloride gave two isomers. The relationship of these isomers has been discussed.